Humacyte (NASDAQ:HUMA) is a biotechnology firm focused on developing and manufacturing human acellular vessels (HAVs) for various medical applications, including vascular and emergency trauma surgery. The company's flagship project, HAV, aims to revolutionize regenerative medicine by providing a bioengineered alternative to synthetic grafts and donor tissues. With a commitment to improving patient outcomes and advancing the field of regenerative medicine, Humacyte's objectives include clinical research, product innovation, and expanding the application of its technologies to address a broad range of medical conditions.